Short answer
SANUWAVE Health, Inc. (SNWV) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 25.1% year over year) with net income of −$1M.
Q3 2026 key financials · XBRL
- Revenue
- $9M
- −25.1% YoY · −11.9% QoQ
- Net income
- −$1M
- −113.7% YoY · −107.6% QoQ
- Operating margin
- -12.5%
- Gross margin
- 77.3%
- EPS (diluted)
- −$0.16
- −117.4% YoY · −100.0% QoQ
Source: XBRL data from the SANUWAVE Health, Inc. (SNWV) Q3 2026 10-Q on SEC EDGAR. USD.
SANUWAVE Health, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $8.6M, down 24% YoY from $11.3M
- Gross margin 77% vs 78% YoY, operating loss $1.1M vs operating income $0.9M
- Worst performer Ultramist® systems: $1.2M, down 73% from $4.4M
- Cash $6.6M, operating cash outflow $29K, financing outflow $4.6M
- Near-term headwinds: weaker capital sales, used-system availability, Nasdaq MVLS compliance by March 22, 2027
Risk Factors
- Newly added covenant risk: JPM Credit Agreement breach as of September 30, 2026, waived under October 28 amendment
- Reimbursement risk: CPT 97610 Medicare payment falling to $314.54 in 2027 from $397.81 in 2026
- Regulatory risk: CMS estimates skin-substitute reimbursement changes reduce Medicare spending nearly 90%
- Market risk: Customer reimbursement pressure contributed to deferred or reduced capital purchases during 2026
- Nasdaq compliance risk: MVLS below $50.0 million threshold, with compliance deadline March 22, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SANUWAVE Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.